Find out more

Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.

The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.

British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.

The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.



BASL ANNUAL MEETING, BLTG Transplant Meeting & BASLNF Meeting 2016
 - View this year's ABSTRACTS CLICK HERE. 


BASL is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.

Members of BASL receive the following benefits:

  • discounted registration rates for the annual meeting and other relevant meetings
  • eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
  • eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.

Click here to find out more about joining us.


26/09/16 Hepatic amyloidosis as a rare differential diagnosis of progressive liver failure
News Type: Clinical News

German researchers have reported a case of hepatic amyloidosis as a rare differential diagnosis of progressive liver failure.

A 63-year-old man presented with newly diagnosed ascites to the researchers’ department. The patient reported occasional alcohol consumption. Viral hepatitis, genetic-metabolic causes as well as hepatic vascular disorders were excluded and ultrasound did not show any signs of liver cirrhosis or intraabdominal malignancy.

Initially, alcoholic hepatitis was suspected. Because of the rapid deterioration of liver function, however, transjugular liver biopsy was performed, showing light chain amyloidosis of kappa isotype.

The researchers suggest that, as the diagnosis of hepatic amyloidosis is challenging, early liver biopsy is mandatory in patients with unexplained acute or chronic liver disease to exclude rare diseases with high mortality.


Hepatic amyloidosis as a rare differential diagnosis of progressive liver failure. Bettinger D, Lutz L, Schultheiß M et al. Dtsch Med Wochenschr. 2016 Sep;141(19):1387-1389

26/09/16 Six weeks sofosbuvir plus ribavirin is not effective in HCV
News Type: Clinical News

While six weeks of sofosbuvir and ribavirin therapy was safe and well tolerated in HCV patients, its efficacy was sub-optimal, a study concluded.

In this open-label study conducted in Australia and New Zealand, 19 adults with recent HCV (68% genotype 1; duration of infection median 37 weeks) received sofosbuvir 400mg daily and weight-based ribavirin for six weeks.

Four reported a symptomatic HCV seroconversion illness, including two with jaundice. At baseline, the median HCV RNA was 5.4 log10 IU/mL and at the end-of-treatment, it was non-quantifiable in 89%. SVR4 and SVR12 were 42% and 32%, respectively.

Treatment failure was because of non-response in two, post-treatment relapse in nine, re-infection in one, and with one loss to follow up.

The regimen was well tolerated with minimal haematological toxicity. SVR12 was related to baseline HCV RNA (≤6 log10 IU/mL, p=0.018) and early on-treatment viral kinetics.

The researchers suggest that further research is needed to determine whether more potent interferon-free direct-acting antiviral regimens will allow treatment duration to be shortened in recent, predominantly asymptomatic, HCV infection.


Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study. Martinello M, Gane E, Hellard M et al. Hepatology. 2016 Sep 17 [Epub ahead of print]

26/09/16 UK patients who have liver transplants abroad get poorer management
News Type: Clinical News

A small number of UK citizens are undergoing liver transplants abroad but their management is of a lower standard than in the UK.

These were the conclusions of researchers at Sheffield’s Royal Hallamshire Hospital, who sent questionnaires to all seven UK liver transplant units enquiring about liver patients receiving transplant abroad. Six of the seven centres responded.

A total of 12 patients were identified as having undergone liver transplantation overseas. The top destinations were India, China and Egypt.

Four units responded to questions regarding pre-transplant screening. One unit reported HBV and HCV screening not taking place. Four units responded to questions regarding post-transplant antimicrobial therapy. This revealed examples of patients inappropriately not receiving valganciclovir, co-trimoxazole, anti-fungal treatment and HBV immunoglobulins.

The researchers add that information transfer between overseas and UK based transplant teams is poor.


A questionnaire based assessment of numbers, motivation and medical care of UK patients undergoing liver transplant abroad. Winter BK, Odedra A, Green S. Travel Med Infect Dis. 2016 Sep 14 [Epub ahead of print]

23/09/16 RCP Dame Sheila Sherlock travelling fellowships in hepatology
News Type: BASL News

Applications are invited for these travelling fellowships, which are funded by a donation from Dr Geraint James in memory of his wife, Dame Sheila Sherlock.

The fellowships offer consultants and trainees the opportunity to learn new techniques and acquire new experiences, ideas and stimulation through travel and the exchange of ideas.

Two travelling fellowships are available, covering a period of 1 month each, and will be offered to one consultant and one trainee. Each fellowship will be for a maximum of £2,000, with the recipients being responsible for funding any additional costs.

Who can apply?
You must have current membership of the RCP.

Applications are open until 16 January 2017 and details on how to apply can be found the the RCP website > HERE.

21/09/16 Alcohol Health Alliance news – September 2016
News Type: BASL News

To view the Alcohol Health Alliance news – September 2016 click > HERE. 

21/09/16 Scottish-Irish Alcohol Policy Report
News Type: BASL News

SHAAP (Scottish Health Action on Alcohol Problems) has released a report that compares alcohol- related problems and welcomes innovative policy responses in Scotland and Ireland. 

Click > HERE to view the report. 

19/09/16 Many vulnerable people do not return for hep screening results
News Type: Clinical News

More than a third of vulnerable people screened for HBV, HCV, HIV and syphilis at out-of-hospital sites, did not return for result, a study in Paris has revealed.

Researchers at nine out-of-hospital screening mobile sites in Paris explored the rates of these infections amongst 341 vulnerable people who were mostly intravenous drug users, sex workers or homeless. 

The proportion of failure to return for results was 38.75%. In multivariate analysis, unemployment was significantly associated with failure to return (odds ratio 4.29), as well as having been screened in the past (odds ratio 4.32). And 18.03% of the patients had a false perception of an immunization against HBV.

In multivariate analysis, having a place of residence protected against a false perception (odds ratio 0.33), while being screened in the past enhanced the risk of a false perception (odds ratio 3.28).

The researchers suggest that using technologies, such as phone texting, might be a partial solution along with rapid diagnostic tests. More information and explanation of the results should be provided, along with specific anti-HBV vaccination campaigns targeting these specific populations.


Out-of-hospital screening for HIV, HBV, HCV and syphilis in a vulnerable population, a public health challenge. Legoupil C, Peltier A, Henry Kagan V et al. AIDS Care. 2016 Sep 14:1-3 [Epub ahead of print]

19/09/16 “Acceptable outcomes” for liver transplant patients who have cardiac surgery
News Type: Clinical News

Liver transplant patients who receive subsequent cardiac surgery have acceptable short-term and long-term outcomes, researchers have concluded.

The researchers, from the University of Alabama at Birmingham School of Medicine, analysed data on 43 patients (median age 60) who underwent cardiac operations at 63 months, on average, after their liver transplants.

There were three operative deaths and 24 late deaths. The patients with a preoperative Model for End-Stage Liver Disease (MELD) score of 13.8 or less had significantly greater survival rates than those with a MELD score greater than 13.8. Patients with a postoperative MELD score of 17 or less had significantly greater survival rates than those with a MELD score greater than 17.

Further analyses showed that postoperative peak creatinine levels were statistically significant predictors of death (relative risk 1.8). The one, five, and 10 year Kaplan-Meier survival rates were 90%, 51%, and 35%, respectively; postoperative mortality rates followed a constant phase model with a hazard of death of 10% per year.


Outcomes of patients who undergo cardiac surgical procedures after liver transplantation. Harrington PB, McAlexander WW, Bryant AS et al. Ann Thorac Surg. 2016 Sep 9 [Epub ahead of print]



29/09/16 - 01/10/16 10th Australasian Viral Hepatitis Conference, Gold Coast Australia
News Type: Other Events

The Australasian Viral Hepatitis Conference is the leading multidisciplinary Viral Hepatitis conference in Australasia. The conference is held biennially and was most recently held in Alice Springs 2014, Auckland 2012 and in Melbourne 2010.

The Australasian Viral Hepatitis Conference attracts a large range of delegates including Viral Hepatitis Specialists, Gastroenterologists, Physicians, General Practitioners, Addiction Medicine specialists, Drug and Alcohol Workers, Nurses, Social Workers, Community Workers, Educators, Pharmaceutical Company Representatives, Basic Scientists, Infectious Disease Specialists, Researchers, National/State & Territory Government Agency Personnel, Non-Government Organisations Personnel, Regional/Area Health Authority Personnel, People Living with Viral Hepatitis.

There has never been a more exciting time to attend the Australasian Viral Hepatitis Conference with major changes happening in the sector to learn about and share with colleagues, so don’t miss out.

For further information and to register click here

Contact details for the conference secretariat can be found below:
P: +61 2 8204 0770

06/10/16 - 08/10/16 European Club Liver Cell Biology – 7th edition, Ascot, UK
News Type: BASL Endorsed Events

This is the 7th Meeting of the European Club for Liver Cell Biology (ECLCB-7)

ECLCB meetings are held every 2-3 years and the goal of the ECLCB meetings is to allow more junior physicians and scientists working in the field of cell biology and pathophysiology of the liver to share data, experience and reagents, as well as create new networks for international collaborations. Over the last fourteen year ECLCB meetings have been attended by EASL members from several EU countries and also by colleagues from the US.

At the last meeting in Treviso (Italy) the United Kingdom undertook the task of organizing the next meeting in 2016 and will take place 6–8 October 2016, at Sunningdale Park, Ascot, UK. De Vere Venues Sunningdale Park is set within 65 acres of stunning landscaped gardens and natural woodland. As well as the modern, purpose-built conference venue, Northcote House, a beautifully refurbished Neo-Georgian mansion nestles within the picturesque grounds and will be available for our meeting.

A call for abstracts will be launched in spring 2016. For more information about the meeting click here

The number of attendees is limited to 80 persons, therefore, early expressions of interest are strongly encouraged. Please send expression of interest to:


10/10/16 - 13/10/16 Trilateral workshop on chronic viral hepatitis in Africa – Cairo, Egypt
News Type: Other Events

Call for participants to a trilateral workshop on: Chronic viral hepatitis in Africa – Sharing the disease burden in Egypt, South Africa and the UK.

The British Council, the Newton Fund, the Musharrafa Foundation, the Science and Technology Development Fund (STDF) and the South African National Research Foundation have launched an initiative to encourage trilateral research collaboration between ambitious young researchers from Egypt, South Africa and the UK.

Under the Researcher Links scheme, The National Liver Institute in Egypt (NLI), University of Cape Town in South Africa (UCT) and Imperial College London, UK, will be holding a workshop on the above theme in Cairo, Egypt from 10th to 13th October 2016.

The workshop is being coordinated by Professors Imam Waked from NLI, Wendy Spearman from UCT and Simon Taylor-Robinson from Imperial, and will have contributions from other leading researchers: including Mark Sonderup (UCT), Robert Wilkinson (Imperial/UCT), Gamal Esmat (Cairo University) and Tumani Corrah (African Research Excellence Fund).

We are now inviting early career researchers (as defined in the Appendix under Eligibility) from Egypt, South Africa and the UK to apply to attend this workshop. Travel and accommodation expenses will be covered by the Researcher Links programme. Click here to view the appendix > Download Call for participants_Cairo viral hepatitis workshop.pdf

The completed application form should be emailed to Dr Peter Norsworthy ( for UK applicants), Dr Asmaa Gomaa (   for Egypt applicants) or Dr Yolande Harley ( ; for South Africa applicants) before the deadline of Monday 1 August 2016.

Click here to download an application form >  Download Application form_Cairo viral hepatitis workshop.pdf

12/10/16 Seventh BHIVA Annual Conference for the Management of HIV/Hepatitis Co-infection in collaboration with BVHG
News Type: BASL Endorsed Events

The British HIV Association (BHIVA), in collaboration with the British Viral Hepatitis Group (BVHG), is to hold a one-day national conference to bring together those directly involved in the care of HIV-infected patients co-infected with hepatitis, as well as those who have a clinical or research interest in the epidemiology, natural history or basic science of viral hepatitis. The conference will take place on Wednesday 12th October 2016 at QEII Centre in London and will be followed by the BHIVA Autumn Conference on 13–14 October 2016.

Programme - the provisional programme information is available to view; please click > here.

Registration - rates and details can be viewed > here.

Please note that there are reduced registration fees for those of non-medic and non-consultant grades. In addition, registration scholarships and community registration places are available.

Case Presentation - there will be a case presentation session during the conference and healthcare professionals are invited to submit cases for review by the facilitators.
• Difficult HIV/Hepatitis Co-infection Case Presentations
To find out more and to apply click > here.  

Key conference topics are:

• Upcoming HCV therapy and ‘difficult-to-treat patients’
• Resistance testing in HCV infection – is it necessary?
• New paradigms in HBV management
• Update on the epidemiology of HBV/HCV in the UK CHIC cohort
• Treatment uptake and outcomes for HCV
• ESLD: referral for transplantation and outcomes
• HCV Research/Stop HCV
• Modelling work
• Collaborations with PHE
• Non-alcoholic fatty liver: a practical approach
• How important is alcohol as a contributor to liver disease in patients with viral hepatitis and HIV?
• Elimination of HCV: a reality?

04/11/16 BVHG Meeting - Viral Hepatitis: State of the Art Review on Hepatitis C, 4 November, London - Book Now
News Type: BASL Events

Venue: Hallam Conference Centre, 44 Hallam St, London, W1W 6JJ

The theme for the meeting is Viral Hepatitis: State of the Art Review on Hepatitis C and will cover:

  • The potential for eradication
  • Debate: re-infection in MSM – to treat or not to treat?
  • State of the art: Treatment

Download a draft programme >  Download Published draft BVHG Programme Nov 16 .pdf


Meetings are free to BASL / BVHG Members.
For non-members a charge of £45 will apply.

We thank our BVHG sponsors for this meeting:
Premier sponsors - AbbVie, Bristol-Myers Squibb, Gilead and Key sponsors - MSD.

04/11/16 BASL School of Viral Hepatology, 4 November, London - Book Now
News Type: BASL Events

Venue: Hallam Conference Centre, 44 Hallam St, London, W1W 6JJ

To view the programme click here >   Download Published School of Viral Hepatology Programme Nov 16.pdf

The School will join with the main BVHG Meeting from 12:00 for the Symposium sponsored by AbbVie followed by lunch.   


Meetings are free to BASL / BVHG Members.
For non-members a charge of £45 will apply.

We thank our School Series sponsors for this meeting:
Premier sponsors - Gilead and Norgine 

11/11/16 - 15/11/16 AASLD 2016 - Boston
News Type: Other Events


The Liver Meeting® will be held at the John B. Hynes Veterans Memorial Convention Center in the heart of downtown Boston from Friday, November 11, 2016 - 12:30 to Tuesday, November 15, 2016 - 1:30.

AASLD is working hard to prepare and make 2016 a banner year – there are lots of exciting changes designed to enhance your experience and offer you more flexibility than ever before. This must-attend event gathers hepatologists from around the world to exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field. 

To read more visit the meeting website > here

16/11/16 MCA Symposium, ‘Alcohol and health harm; what can doctors, nurses and other professionals do? - Royal College of Surgeons, London
News Type: Other Events

The 2016 Medical Council on Alcohol (MCA) Symposium, ‘Alcohol and health harm; what can doctors, nurses and other professionals do?’, will take place on 16th November at the Royal College of Surgeons, London.

In this symposium, they will focus on the ways in which health professionals from different disciplines, sectors and specialties can act to reduce these harms. It will cover approaches including brief interventions in different settings, primary care and commissioning, inequalities and public health, addiction medicine and accident and emergency.

For more details > click here to visit the MCA website.


Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.

Ward membership benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September.

To find out how to apply click here

British Viral Hepatitis Group (BVHG) Committee Chair Vacancy - due to the current post holder having served their tenure, BASL are seeking nominations/ expressions of interest for the post. Please send your nominations by Monday 3rd October 2016, 17:00. To find out more visit the BASL News page - CLICK HERE.

Click here to view the Events Newsletter - August
Click here to view the Newsletter - June 

Learning Toolkits

The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account

Quick Links

BASL is connected to a number of national initiaives that you might be interested in.